Thursday, October 14, 2021 9:15:28 AM
Marjac
More
“A party seeking to intervene must do so”As soon as he knows or has reason to know that his interests might be adversely affected by the outcome of the litigation”
The defendants assert that Epadi in effect should have instigated its Rule 24 /Rule 60 action at the outset of the litigation process some 4.5 years ago.the reality is that it was only at the point where it became apparent that the K table had been cropped and introduced into the proceedings by the defendants. It was further a reasonable expectation that A would have themselves litigated on this matter.
However the passage of time from the revelation of the cropped table introduction to the Ruke 24/rule 60 proceedings was only a matter of x months and not the 4.5 years that the defendants seek to divert the courts attention to on the issue of the timely bringing it Rule24/rule 60 action.
The defendants put it this way “members of Epadi should have know from the outset of the litigation that they had a stake in the outcome of Amarins patent litigation suit against generic competition. This proposition from the defendants is simply preposterous . If it were true all parties who had a stake in litigation suit outcomes of this kind would have to institute Rule24 /rule 60 actions at the very beginning of every patent litigation suit - even though there was at that first point in time no justifiable cause to bring such an action or indeed evidence to support such an action.
The defendants for their own protection from exposure of their fraud seek to obscure the simple and obvious fact that the basis of Epadi bringing this case is that at the very end of these proceedings a fraud was practised on the court and it is this that gave rise to Epadi taking interventionist action. The evidence that such a fraud was perpetrated was only revealed via the introduction of the cropped K table .
Alm
More to follow
More
“A party seeking to intervene must do so”As soon as he knows or has reason to know that his interests might be adversely affected by the outcome of the litigation”
The defendants assert that Epadi in effect should have instigated its Rule 24 /Rule 60 action at the outset of the litigation process some 4.5 years ago.the reality is that it was only at the point where it became apparent that the K table had been cropped and introduced into the proceedings by the defendants. It was further a reasonable expectation that A would have themselves litigated on this matter.
However the passage of time from the revelation of the cropped table introduction to the Ruke 24/rule 60 proceedings was only a matter of x months and not the 4.5 years that the defendants seek to divert the courts attention to on the issue of the timely bringing it Rule24/rule 60 action.
The defendants put it this way “members of Epadi should have know from the outset of the litigation that they had a stake in the outcome of Amarins patent litigation suit against generic competition. This proposition from the defendants is simply preposterous . If it were true all parties who had a stake in litigation suit outcomes of this kind would have to institute Rule24 /rule 60 actions at the very beginning of every patent litigation suit - even though there was at that first point in time no justifiable cause to bring such an action or indeed evidence to support such an action.
The defendants for their own protection from exposure of their fraud seek to obscure the simple and obvious fact that the basis of Epadi bringing this case is that at the very end of these proceedings a fraud was practised on the court and it is this that gave rise to Epadi taking interventionist action. The evidence that such a fraud was perpetrated was only revealed via the introduction of the cropped K table .
Alm
More to follow
Recent AMRN News
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
